28
26
14
24
28
22 Cover Story
12
The cover story of the month titled: Advance stem cell therapy with biodegradable scaffold: New technology is aimed at central nervous system diseases and injuries Materials provided by Rutgers University. Scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer's and Parkinson's diseases, article also appeared in the Nature communications, 2018
Featured article
16
Added to this, the current edition has a special featured article Messe India and Indian Medical Association signed a memorandum of understanding to work together, Pre event coverage for Medika India event organised by Messe India
Product Launches
22
The edition also covers recent Healthcare news articles and product launches collected from worldwide sources to update the readers with the current trends in the industry
Augurex and Quidel Partner to Distribute 14-3-3Ρ Assay
22
Augurex, Vancouver, BC, Canada, and Quidel, San Diego, have recently announced their launch of the JointStat 14-3-3Ρ research use only enzyme-linked immunosorbent assay.
Olympus Technology Helps to Create AIBased Tool for Diagnostic Pathology
22
Olympus Corp, Waltham, Mass, has recently described the findings of a research program that has the potential to help streamline the workload of clinical pathologists through the use of digital imaging and artificial intelligence systems.
BD Launches Molecular Test for Tuberculosis
24
Becton, Dickinson and Co (BD), Franklin Lakes, NJ, has announced the availability of the BD Max MDR-TB panel in Europe.
Microbioz India, December 2018 8
Cover Story
Advance stem cell therapy with biodegradable scaffold New technology is aimed at central nervous system diseases and injuries cientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer's and Parkinson's diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries. Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete differentiation of cells and limited growth of neural connections. Rutgers scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer's and Parkinson's diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries. Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete differentiation of cells and limited growth of neural connections. So, Rutgers scientists designed bio-scaffolds that mimic natural tissue and got good results in test tubes and mice, according to a study in Nature Communications. These nano-size scaffolds hold promise for advanced stem cell transplantation and neural tissue engineering. Stem cell therapy leads to stem cells becoming neurons and can restore neural circuits.
S
"It's been a major challenge to develop a reliable therapeutic method for treating central nervous system diseases and injuries," said study senior author KiBum Lee, a professor in the Department of Chemistry and Chemical Biology at Rutgers University-New Brunswick. "Our enhanced stem cell transplantation approach is an innovative potential solution."
Microbioz India, December 2018
12
Cover Story
The researchers, in cooperation with neuroscientists and clinicians, plan to test the nano-scaffolds in larger animals and eventually move to clinical trials for treating spinal cord injury. The scaffold-based technology also shows promise for regenerative medicine.
Story Source: Is for information purposes: Materials provided by Rutgers University. Note: Content may be edited for style and length.
Journal Reference: Letao Yang, Sy-Tsong Dean Chueng, Ying Li, Misaal Patel, Christopher Rathnam, Gangotri Dey, Lu Wang, Li Cai, Ki-Bum Lee. A biodegradable hybrid inorganic nanoscaffold for advanced stem cell therapy. Nature Communications, 2018; 9 (1) DOI: 10.1038/s41467-018-05599-2
Microbioz India, December 2018
14
Guest Post
Messe India and Indian Medical Association signed a memorandum of understanding to work together
New Delhi, October 31, 2018 – Messe India &Indian Medical Association (IMA) signed a memorandum of understanding to work together and supportfor upcoming exhibition MEDIKA INDIA.Both the parties have agreed to facilitate exchange programs betweenexhibitors and hospitals by conducting one to one meetingduring MEDIKA INDIA, 2019. Signing the MOU were Hon. President of the Indian Medical Association- Dr. Ravi Wankhedkarand Director of IndMesse Trade Fairs Pvt Ltd.- Mr. Sachin Patil. As a part of this special partnership, Indian doctors will be encouraged to participate at MEDIKA India, Hyderabad. Together with Hospitals Board of India(HBI),IMA will organise aBuyer Seller meet. HBI will bring delegation from leading hospitals and also from upcoming hospitals to facilitate direct contact between exhibitors and buyersthrough prescheduled meetings. IMA will also help the MEDIKA India in providing regular exhibition updates to their doctors and updating their medical Journals.
Talking on the occasion, Dr.Ravi Wankhedkar, National President of the IMA said, “We are extremely happy to announce this partnership with the MEDIKA India. This will help us not only recording our requirements for medical devices with exhibitors but will also help our doctors to understand the latest technologies& solutions available todayand also give manufacturer the opportunity to research and learn in real-life settings.
Adding to this, Mr. Sachin Patil – Director ofIndMesse Trade Fairs Pvt Ltd said, “It is an extremely proud moment to partner with the Indian Medical Association and I hope that together we can make this a better platform for both doctors and Exhibitors.” IMA believe that the common understanding in the MoU will go a long way towards facilitating trade opportunities and strategic alliances in the healthcare sector
Microbioz India, December 2018 16
Guest Post About MEDIKA India: MEDIKA India is scheduled from 3rd – 5th May 2019 at Hyderabad International Trade Expositions Limited. MEDIKA India is a B2B exhibition focussing on medical technology & equipment used in the field of healthcare sectors - hospitals, clinics, laboratories etc. With 200+ exhibitors and 15000+ trade visitors from 12+ countries, the trade fair will feature an array of technology, equipment & products to address ever-increasing industry demand in the region. It will act as a business platform for
regional manufacturers and suppliers from the medical and healthcare sectors. About IMA: Indian Medical Association is the only representative, national voluntary organization of Doctors of Modern Scientific System of Medicine, which looks after the interest of doctors as well as the well-being of the community at large. It has its Headquarter in Delhi and State / Terr. Branches in 29 States and Union Territories. It has over 2, 53,000 doctors as its members through more than 1650 active local branches spread across the country.
Guest Post
India is booming and the MEDICAlliance is booming with it MEDICAL FAIR INDIA: firmly established and successful fixture for 25 years – from 21 – 23 February 2019 back again in New Delhi The Indian market for medical device technology and medical products has been booming for years and will also be among the fastest growing markets worldwide in the coming years. Experts forecast the market volume to rise to US$ 50 billion by 2025. And this market, considered the fourth biggest in Asia after Japan, China and South Korea, has counted on an element of continuity for nearly 25 years now: MEDICAL FAIR INDIA, a trade fair in Messe Düsseldorf Group’s MEDICAlliance. “MEDICAL FAIR INDIA has been the leading industry platform of this subcontinent for many years now. Alternating between Mumbai and New Delhi on an annual basis it has raced from one record to the next always in sync with the market, “explains Horst Giesen, Global Portfolio Director Health & Medical Technologies at Messe Düsseldorf, commenting on the constantly rising numbers of exhibitors and visitors. Following on from the results of the events held this year (Mumbai) and in 2017 (New Delhi) once again to the tune of 15,000 trade visitors and in excess of 500 exhibitors are expected to attend the 25th edition of MEDICAL FAIR INDIA held from 21 – 23 February 2019 at the Pragati Maidan Exhibition Center in New Delhi. Planning is already in full swing in terms of both exhibitor registrations and putting together an attractive programme of side events. Forming an integral part of the trade fair, these include CLIN LAB INDIA, for example, a conference conceived of, and organised by Scherago in cooperation with the Messe Düsseldorf Group (encompassing an exhibition area on trend themes in laboratory medicine) or the FTR4H Lab & Lounge as a digital health platform. Centre stage here are product ideas developed by start-ups, expert exchanges and networking on all exciting topics associated with digital transformation in healthcare (e.g. connection, mobile health, eHealth, Internet of Things, Big Data and innovative health-IT solutions). A new addition will be the themed area REHAINDIA
presenting products and services related to nursing care and rehabilitation. Due to the high demand in previous years the big Europa stand is also undergoing planning again: companies from all European states are given an opportunity here to present their products to the Indian market inexpensively and enjoying a variety of services at the joint pavilion managed by Messe Düsseldorf. Furthermore, there will also be an official German Pavilion subsidised by the Federal Ministry of Economics. Focal themes covered by the ranges on show at MEDICAL FAIR INDIA 2019 include medical products and medical device technology, laboratory technology and diagnostics, furnishings and furniture for Clinics and Health Centres and the Health IT and Mobile Health solution – the area that is very on trend throughout the world currently. With its theme the event addresses decisionmakers from the medical field (e.g. physicians and health professionals) and top hospital managers. But it is just as attractive for architects and building planners, for business consultants and science and research protagonists. The next MEDICAL FAIR INDIA will be held from 21 to 23 February 2019 – in keeping with the schedule – in New Delhi, at Pragati Maidan. All details relating to MEDICAL FAIR INDIA are available online at: http://www.medicalfairindia.com. About MEDICAL FAIR INDIA MEDICAL FAIR INDIA is a trade fair in the product family MEDICAlliance. It is held by Messe Düsseldorf India, a subsidiary of Messe Düsseldorf, and takes place in close cooperation with the team of Düsseldorf’s leading global trade fair MEDICA. All the facts, figures and information on MEDICAlliance trade fairs are available online at http://www.medicalliance.global. For further queries, please contact: Messe Düsseldorf India Pvt. Ltd. Siddhartha Mishra / Akshi Chawla Tel: +91 11 4855-0061/ -0067 E-Mail: MishraS@md-india.com E-Mail: ChawlaA@md-india.com
Microbioz India, December 2018 20
Product Launch
Augurex and Quidel Partner to Distribute 143-3η Assay Augurex, Vancouver, BC, Canada, and Quidel, San Diego, have recently announced their launch of the JointStat 14-3-3η research use only enzyme-linked immunosorbent assay. The companies’ joint distribution arrangement will get testing for the 14-3-3η protein into the hands of more investigators worldwide— including key opinion leaders and pharmaceutical companies—to advance and grow the body of data for the novel joint damage biomarker in autoimmune diseases. There is increasing international momentum to investigate the role of 14-3-3η in various autoimmune diseases with joint involvement. In addition to rheumatoid arthritis, where the largest body of 14-3-3η data exists, conditions such as inflammatory bowel disease, psoriasis, and systemic lupus erythematosus are also associated with a high incidence of arthritis, secondary to their primary autoimmune disease. The protein 14-3-3η informs mechanistic joint damage processes common to such conditions, allowing novel biochemical pathways and therapeutic options to be investigated from the basic science level, right through to disease prevention and controlled clinical remission.
Norma Biln, Augurex. For Augurex, the synergy with Quidel builds on the companies’ strong and growing bone and complement pathway marker business, which has an excellent distribution fit for client groups interested in investigating 14-3-3η. “Most importantly, we are committed to working with companies who not only have commercial strength but also share similar guiding principles to ours, including integrity, patient focus, and optimism,” says Norma Biln, CEO of Augurex. “Ultimately this benefits all
stakeholders, especially patients who are waiting for solutions.” Story source and Credit: Augurex and Quidel.
Olympus Technology Helps to Create AI-Based Tool for Diagnostic Pathology
Olympus Corp, Waltham, Mass, has recently described the findings of a research program that has the potential to help streamline the workload of clinical pathologists through the use of digital imaging and artificial intelligence systems. The research program, “A New Approach to Develop Computer-Aided Diagnosis Using Artificial Intelligence for Gastric Biopsy Specimens,” was conducted jointly with Kiyomi Taniyama, MD, PhD, president of Japan’s Kure Medical Center and Chugoku Cancer Center. Initiated in 2017, the research program coupled Taniyama’s expertise in diagnostic pathology of the gastric system and digital pathology with Olympus’ imaging system technology and proficiency in artificial intelligence development.
Microbioz India, December 2018 22
Product Launch
Kiyomi Taniyama, MD, PhD, Kure Medical Center and Chugoku Cancer Center. Making use of the company’s proprietary deeplearning technology, Olympus has been working to develop a computer-aided diagnostic solution using artificial intelligence for diagnostic pathology. For the research program, Olympus applied its deep-learning technology to a review of gastric biopsy specimens collected at the Kure Medical Center and Chugoku Cancer Center between 2015 and 2018. The outcome was the creation of a multiresolutional convolutional neural network (CNN), a network structure that is widely used in deep-learning technology for image analysis. The deep-learning technology’s unique CNN was designed to analyze the features shown in digital images of pathology specimens. Such a structure effectively realizes the learning features of input data. Story source and Credit; Olympus
BD Launches Molecular Test for Tuberculosis
Becton, Dickinson and Co (BD), Franklin Lakes, NJ, has announced the availability of the BD Max MDR-TB panel in Europe. Clinicians can use the test to simultaneously detect the bacteria that cause tuberculosis (TB) and to determine whether the bacteria contain mutations associated with resistance to two important first-line drugs—isoniazid (INH) and
rifampicin (RIF)—enhancing the information available to direct optimal treatment for patients. Every year, about 10 million people develop TB, and close to 2 million die from the disease, making it the leading cause of death from a single infectious agent. With proper detection and treatment, TB is curable. Multidrug-resistant TB (MDR-TB), defined as resistance to both INH and RIF, remains a critical hurdle in the fight to eradicate TB, as patients with resistance to therapy will not benefit from those medicines and could spread the resistant forms of the disease to others.1 The BD Max MDR-TB panel is an in vitro diagnostic with CE mark, now available in Europe. The single polymerase chain reactionbased molecular diagnostic is an integrated test intended to help in the detection and diagnosis of TB, including INH- and RIF-resistant strains of the disease.
Nikos Pavlidis, BD Diagnostic Systems. BD has a long history in TB diagnostics, having launched the first automated liquid culture system, the BD Bactec MGIT system, for comprehensive testing for drug susceptibility and resistance. The new BD Max MDR-TB assay complements this technology, enabling clinicians to rapidly test for TB and multidrug resistance as a first-line test, and then use the BD Bactec MGIT system for broader drug susceptibility testing and patient monitoring. “We continue to focus on improving the diagnosis of TB so that we can provide clinicians with the best tools for identifying effective treatments for their patients,” says Nikos Pavlidis, vice president and general manager for molecular diagnostics and women’s health at BD Diagnostic Systems. “This new test is a big step forward for clinical practice, as antimicrobial resistance has made this identification more complex. With the BD Max MDR-TB panel and BD Bactec MGIT products, BD is able to offer laboratories a suite of tools for effective and accurate patient diagnosis and management.”
Microbioz India, December 2018
24
Product Launch
Charles Cooper, MD, BD Diagnostic Systems. “As antimicrobial resistance becomes a greater problem in TB, understanding the drugresistance profile has become an increasingly important tool for successful treatment of individual patients,” says Charles Cooper, MD, vice president for medical affairs at BD Diagnostic Systems. “Our global clinical trial of the BD Max MDR-TB assay demonstrated that the assay can reliably detect both INH and RIF resistance. In addition, this assay can rapidly provide clinicians with valuable information necessary to manage patients with TB infections.” Story source and Credit : Becton, Dickinson and Co.
MilliporeSigma Sells Flow Cytometry Business to Luminex Published on November 28, 2018
MilliporeSigma, Burlington, Mass, has signed a definitive agreement to sell its flow cytometry unit to Luminex Corp, Austin, Texas, for $75 million. Closing of the transaction, expected by the end of 2018, is subject to customary closing conditions.
Udit Batra, MilliporeSigma. Upon completion of the transaction, Luminex will own the flow cytometry platforms Amnis and Guava as well as the associated reagents under those brands. The transaction includes a portfolio of leading technologies serving the research space. MilliporeSigma continues to actively manage its comprehensive portfolio by tapping into innovation and placing it in the best hands to continuously drive value for customers. “This is an exciting opportunity for both of our organizations, and I would like to extend my sincerest thanks to our committed colleagues,” says Udit Batra, CEO of MilliporeSigma. “Luminex is a long and trusted partner who has provided a wide range of solutions for clinical diagnostics, pharmaceutical drug discovery, and biomedical research. Luminex shares our conviction to solve the toughest problems in life science. This will be a great new home for the team to build on their expertise and introduce more solutions to a broader base. At the same time, our existing customers will get access to Luminex’s respected product portfolio.”
Homi Shamir, Luminex. The acquisition expands Luminex’s existing offering of flow-based detection systems, which is focused on its xMAP multiplexing technology, with more than 15,000 xMAP systems sold worldwide. MilliporeSigma’s ImageStream X Mark II imaging flow cytometer, for example, has extremely high sensitivity and is used to detect and characterize small particles. “As innovators in flow-based technologies, we are excited to acquire the flow cytometry assets of our existing long-term partner MilliporeSigma, thereby expanding our portfolio of detection systems to address researchers
Microbioz India, December 2018 26
Product Launch interested in cellular analysis,” says Homi Shamir, president and CEO of Luminex. “We look forward to welcoming the talented MilliporeSigma team to the Luminex family.” Story source and Credit: Luminex.
LGC Maine Standards Launches Validate Body Fluids Kit
LGC Maine Standards, Cumberland Foreside, Me, has expanded its body fluids product line with the launch of its Validate Body Fluids kit, for easier linearity and calibration verification. Provided in a simulated body fluid matrix, the kit will assist in the documentation of linearity, calibration verification, and verification of the reportable range for albumin, amylase, cholesterol, creatinine, glucose, lactate, lactate dehydrogenase, total protein, triglycerides, and urea nitrogen. Each Validate Body Fluids kit is liquid, ready-touse, and prepared using the CLSI EP06-A ‘equal delta’ method of sample preparation, providing five distinct concentrations to establish the reportable range of the assay. Users dispense the solution from each dropper bottle directly into five sample cups, and run in replicates. Use of the product augments daily quality control protocols and assists labs in fulfilling various requirements, such as establishing the analytical measurement range and reportable range for linearity and calibration verification. Story source and Credit: LGC Maine Standards.
DiaSorin Molecular Attains CE Mark for Simplexa Group B Strep Direct Molecular Assay
DiaSorin Molecular LLC, Cypress, Calif, recently announced that it has attained CE marking for its new SimplexaGroup B Strep Direct assay. Designed for use on the company’s Liaison MDx instrument, the highly sensitive assay enables the direct in vitrodetection of Group B Streptococcus (GBS) DNA. GBS infection is a significant challenge in the health management of women and newborns. The new assay is more specific than traditional testing methods, and features a fast and efficient workflow. The assay has also been submitted for FDA clearance under the agency’s premarket notification (510(k)) process.
Michelle Tabb, PhD, DiaSorin Molecular. GBS infection is a leading cause of early-onset neonatal sepsis. An estimated one in five pregnant women around the world carries GBS
Microbioz India, December 2018
28
Product Launch bacteria, which is a major, yet preventable, cause of maternal and infant infection globally. Vertical transmission of GBS to the newborn can result in an invasive infection known as early onset disease (EOD). Infants with EOD will present with fever, lethargy, sepsis, pneumonia and, more rarely, meningitis within the first 24 to 48 hours of life. The World Health Organization estimates that GBS causes an estimated 150,000 preventable stillbirths and infant deaths every year.
“With this CE-marked assay we are pleased to enter the women’s health market,” says Michelle Tabb, chief scientific officer at DiaSorin Molecular.
“Our company is driven to help hospitals and clinical labs provide excellent patient care through highquality molecular assays and we are proud to add GBS to the important disease areas we address.” Story source and credit: DiaSorin Molecular.
RNI NUMBER: UPENG/2017/73675